Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D. Döhner H, et al. Among authors: beach cl. Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293. Blood. 2022. PMID: 35960871 Free PMC article. Clinical Trial.
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. Dombret H, et al. Among authors: beach cl. Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18. Blood. 2015. PMID: 25987659 Free PMC article. Clinical Trial.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. Among authors: beach cl. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F, Roboz GJ, Wei AH, Döhner H, Pocock C, Selleslag D, Montesinos P, Sayar H, Musso M, Figuera-Alvarez A, Safah H, Tse W, Sohn SK, Hiwase D, Chevassut T, Pierdomenico F, La Torre I, Skikne B, Bailey R, Zhong J, Beach CL, Dombret H. Ravandi F, et al. Among authors: beach cl. J Hematol Oncol. 2021 Aug 28;14(1):133. doi: 10.1186/s13045-021-01142-x. J Hematol Oncol. 2021. PMID: 34454540 Free PMC article. Clinical Trial.
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH. Roboz GJ, et al. Among authors: beach cl. Haematologica. 2021 Dec 1;106(12):3240-3244. doi: 10.3324/haematol.2021.279174. Haematologica. 2021. PMID: 34551506 Free PMC article. Clinical Trial. No abstract available.
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Garcia-Manero G, Döhner H, Wei AH, La Torre I, Skikne B, Beach CL, Santini V. Garcia-Manero G, et al. Among authors: beach cl. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):236-250. doi: 10.1016/j.clml.2021.09.021. Epub 2021 Oct 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34758945 Free article. Review.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne B, Zhong J, Beach CL, Risueño A, Menezes DL, Ossenkoppele G, Döhner H. Roboz GJ, et al. Among authors: beach cl. Blood. 2022 Apr 7;139(14):2145-2155. doi: 10.1182/blood.2021013404. Blood. 2022. PMID: 34995344 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36163843
Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
Seymour JF, Döhner H, Minden MD, Stone R, Gambini D, Dougherty D, Beach CL, Weaver J, Dombret H. Seymour JF, et al. Among authors: beach cl. Leuk Lymphoma. 2017 Jun;58(6):1412-1423. doi: 10.1080/10428194.2016.1243680. Epub 2016 Oct 14. Leuk Lymphoma. 2017. PMID: 27739920
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H. Seymour JF, et al. Among authors: beach cl. BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6. BMC Cancer. 2017. PMID: 29241450 Free PMC article. Clinical Trial.
62 results